Essential Partners
HAE icon

Essential Partners’s Haemonetics HAE Stock Holding History

Essential Partners’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$113K Sell
1,077
-84
-7% -$7.82K 0.05% 392
2026
Q2 		$87.1K Sell
1,161
-525
-31% -$33.7K 0.04% 456
2026
Q1 		$95K Sell
1,686
-11
-0.6% -$716 0.03% 435
2025
Q4 		$136K Buy
1,697
+716
+73% +$48.1K 0.04% 380
2025
Q3 		$47.8K Buy
981
+907
+1,226% +$56.1K 0.02% 603
2025
Q2 		$5.52K Buy
+74
New +$4.9K ﹤0.01% 1022

Other funds holding HAE

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Fort Washington Investment Advisors
Fort Washington Investment Advisors Cincinnati, Ohio $19.7B AUM 20.11% 1-Year Est. Return
Isthmus Partners
Isthmus Partners Madison, Wisconsin $1.04B AUM 19.97% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
QV Investors
QV Investors Calgary, Alberta, Canada $1.36B AUM 20.86% 1-Year Est. Return
Cardinal Capital Management Inc (North Carolina)
Cardinal Capital Management Inc (North Carolina) Raleigh, North Carolina $861M AUM 27.19% 1-Year Est. Return
Skylands Capital
Skylands Capital Milwaukee, Wisconsin $762M AUM 14.92% 1-Year Est. Return
Pinnacle Associates
Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Confluence Investment Management
Confluence Investment Management St. Louis, Missouri $5.97B AUM 5.11% 1-Year Est. Return

Essential Partners's HAE Position: Q3 2026 in Review

Essential Partners reduced its Haemonetics (HAE) stake by 7.2% in Q3 2026, selling an estimated $7.82K and leaving 1,077 shares worth $113K. The position accounts for 0.05% of the portfolio, ranked #392.

Essential Partners first reported a position in HAE in Q2 2025 and has held it in 6 quarters since. The position peaked at $136K in Q4 2025. 40 funds tracked by Wall St. Rank hold HAE as of Q3 2026.

  • Essential Partners held 1,077 shares of Haemonetics worth $113K as of Q3 2026.
  • Essential Partners sold 84 Haemonetics shares in Q3 2026, an estimated $7.82K.
  • Haemonetics made up 0.05% of Essential Partners's portfolio in Q3 2026, its #392 holding.
  • Essential Partners first reported a position in Haemonetics in Q2 2025 and has held it in 6 quarters since.
  • Essential Partners's Haemonetics position peaked at $136K in Q4 2025.
  • 40 funds tracked by Wall St. Rank held Haemonetics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.